PRME

SEC source: 0001894562-25-000047 · wk-form4_1754440988.xml · derivative · entry 2

Kelly Michael Aaron · CIK 0001769668 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,510

Underlying: Common Stock · 13,510 shares

Expires 2031-11-24

F1 · kind: Effective as of August 1, 2025 (the "Repricing Date"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Stock Option and Grant Plan, as amended (the "2019 Plan") and/or the 2022 Stock Option and Incentive Plan (the "2022 Plan" and, together with the 2019 Plan, the "Plans"), which reduced the per share exercise price of each Repriced Option to $4.04, representing the closing price of the Issuer's common stock on The Nasdaq Global Market on the Repricing Date (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect.

F1 · price: Effective as of August 1, 2025 (the "Repricing Date"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Stock Option and Grant Plan, as amended (the "2019 Plan") and/or the 2022 Stock Option and Incentive Plan (the "2022 Plan" and, together with the 2019 Plan, the "Plans"), which reduced the per share exercise price of each Repriced Option to $4.04, representing the closing price of the Issuer's common stock on The Nasdaq Global Market on the Repricing Date (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect.

F2 · derivative.exercise_date: This stock option award was issued pursuant to the 2019 Plan and/or the 2022 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.

SEC source: 0001894562-25-000047 · wk-form4_1754440988.xml · derivative · entry 1

Kelly Michael Aaron · CIK 0001769668 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 13,510 shares

Expires 2031-11-24

F1 · kind: Effective as of August 1, 2025 (the "Repricing Date"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Stock Option and Grant Plan, as amended (the "2019 Plan") and/or the 2022 Stock Option and Incentive Plan (the "2022 Plan" and, together with the 2019 Plan, the "Plans"), which reduced the per share exercise price of each Repriced Option to $4.04, representing the closing price of the Issuer's common stock on The Nasdaq Global Market on the Repricing Date (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect.

F1 · price: Effective as of August 1, 2025 (the "Repricing Date"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Stock Option and Grant Plan, as amended (the "2019 Plan") and/or the 2022 Stock Option and Incentive Plan (the "2022 Plan" and, together with the 2019 Plan, the "Plans"), which reduced the per share exercise price of each Repriced Option to $4.04, representing the closing price of the Issuer's common stock on The Nasdaq Global Market on the Repricing Date (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect.

F2 · derivative.exercise_date: This stock option award was issued pursuant to the 2019 Plan and/or the 2022 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.

SEC source: 0001894562-25-000046 · wk-form4_1754440982.xml · derivative · entry 8

Foster-Cheek Kaye I · CIK 0001312622 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 45,000

Underlying: Common Stock · 45,000 shares

Expires 2034-06-12

F1 · kind: Effective as of August 1, 2025 (the "Repricing Date"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Stock Option and Grant Plan, as amended (the "2019 Plan") and/or the 2022 Stock Option and Incentive Plan (the "2022 Plan" and, together with the 2019 Plan, the "Plans"), which reduced the per share exercise price of each Repriced Option to $4.04, representing the closing price of the Issuer's common stock on The Nasdaq Global Market on the Repricing Date (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect.

F1 · price: Effective as of August 1, 2025 (the "Repricing Date"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Stock Option and Grant Plan, as amended (the "2019 Plan") and/or the 2022 Stock Option and Incentive Plan (the "2022 Plan" and, together with the 2019 Plan, the "Plans"), which reduced the per share exercise price of each Repriced Option to $4.04, representing the closing price of the Issuer's common stock on The Nasdaq Global Market on the Repricing Date (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect.

F2 · derivative.exercise_date: This stock option award was issued pursuant to the 2019 Plan and/or the 2022 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.

SEC source: 0001894562-25-000046 · wk-form4_1754440982.xml · derivative · entry 7

Foster-Cheek Kaye I · CIK 0001312622 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 45,000 shares

Expires 2034-06-12

F1 · kind: Effective as of August 1, 2025 (the "Repricing Date"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Stock Option and Grant Plan, as amended (the "2019 Plan") and/or the 2022 Stock Option and Incentive Plan (the "2022 Plan" and, together with the 2019 Plan, the "Plans"), which reduced the per share exercise price of each Repriced Option to $4.04, representing the closing price of the Issuer's common stock on The Nasdaq Global Market on the Repricing Date (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect.

F1 · price: Effective as of August 1, 2025 (the "Repricing Date"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Stock Option and Grant Plan, as amended (the "2019 Plan") and/or the 2022 Stock Option and Incentive Plan (the "2022 Plan" and, together with the 2019 Plan, the "Plans"), which reduced the per share exercise price of each Repriced Option to $4.04, representing the closing price of the Issuer's common stock on The Nasdaq Global Market on the Repricing Date (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect.

F2 · derivative.exercise_date: This stock option award was issued pursuant to the 2019 Plan and/or the 2022 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.

SEC source: 0001894562-25-000046 · wk-form4_1754440982.xml · derivative · entry 6

Foster-Cheek Kaye I · CIK 0001312622 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 39,062

Underlying: Common Stock · 39,062 shares

Expires 2033-06-14

F1 · kind: Effective as of August 1, 2025 (the "Repricing Date"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Stock Option and Grant Plan, as amended (the "2019 Plan") and/or the 2022 Stock Option and Incentive Plan (the "2022 Plan" and, together with the 2019 Plan, the "Plans"), which reduced the per share exercise price of each Repriced Option to $4.04, representing the closing price of the Issuer's common stock on The Nasdaq Global Market on the Repricing Date (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect.

F1 · price: Effective as of August 1, 2025 (the "Repricing Date"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Stock Option and Grant Plan, as amended (the "2019 Plan") and/or the 2022 Stock Option and Incentive Plan (the "2022 Plan" and, together with the 2019 Plan, the "Plans"), which reduced the per share exercise price of each Repriced Option to $4.04, representing the closing price of the Issuer's common stock on The Nasdaq Global Market on the Repricing Date (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect.

F2 · derivative.exercise_date: This stock option award was issued pursuant to the 2019 Plan and/or the 2022 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.

SEC source: 0001894562-25-000046 · wk-form4_1754440982.xml · derivative · entry 5

Foster-Cheek Kaye I · CIK 0001312622 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 39,062 shares

Expires 2033-06-14

F1 · kind: Effective as of August 1, 2025 (the "Repricing Date"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Stock Option and Grant Plan, as amended (the "2019 Plan") and/or the 2022 Stock Option and Incentive Plan (the "2022 Plan" and, together with the 2019 Plan, the "Plans"), which reduced the per share exercise price of each Repriced Option to $4.04, representing the closing price of the Issuer's common stock on The Nasdaq Global Market on the Repricing Date (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect.

F1 · price: Effective as of August 1, 2025 (the "Repricing Date"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Stock Option and Grant Plan, as amended (the "2019 Plan") and/or the 2022 Stock Option and Incentive Plan (the "2022 Plan" and, together with the 2019 Plan, the "Plans"), which reduced the per share exercise price of each Repriced Option to $4.04, representing the closing price of the Issuer's common stock on The Nasdaq Global Market on the Repricing Date (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect.

F2 · derivative.exercise_date: This stock option award was issued pursuant to the 2019 Plan and/or the 2022 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.

SEC source: 0001894562-25-000046 · wk-form4_1754440982.xml · derivative · entry 4

Foster-Cheek Kaye I · CIK 0001312622 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,006

Underlying: Common Stock · 9,006 shares

Expires 2032-10-19

F1 · kind: Effective as of August 1, 2025 (the "Repricing Date"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Stock Option and Grant Plan, as amended (the "2019 Plan") and/or the 2022 Stock Option and Incentive Plan (the "2022 Plan" and, together with the 2019 Plan, the "Plans"), which reduced the per share exercise price of each Repriced Option to $4.04, representing the closing price of the Issuer's common stock on The Nasdaq Global Market on the Repricing Date (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect.

F1 · price: Effective as of August 1, 2025 (the "Repricing Date"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Stock Option and Grant Plan, as amended (the "2019 Plan") and/or the 2022 Stock Option and Incentive Plan (the "2022 Plan" and, together with the 2019 Plan, the "Plans"), which reduced the per share exercise price of each Repriced Option to $4.04, representing the closing price of the Issuer's common stock on The Nasdaq Global Market on the Repricing Date (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect.

F2 · derivative.exercise_date: This stock option award was issued pursuant to the 2019 Plan and/or the 2022 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.

SEC source: 0001894562-25-000046 · wk-form4_1754440982.xml · derivative · entry 3

Foster-Cheek Kaye I · CIK 0001312622 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 9,006 shares

Expires 2032-10-19

F1 · kind: Effective as of August 1, 2025 (the "Repricing Date"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Stock Option and Grant Plan, as amended (the "2019 Plan") and/or the 2022 Stock Option and Incentive Plan (the "2022 Plan" and, together with the 2019 Plan, the "Plans"), which reduced the per share exercise price of each Repriced Option to $4.04, representing the closing price of the Issuer's common stock on The Nasdaq Global Market on the Repricing Date (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect.

F1 · price: Effective as of August 1, 2025 (the "Repricing Date"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Stock Option and Grant Plan, as amended (the "2019 Plan") and/or the 2022 Stock Option and Incentive Plan (the "2022 Plan" and, together with the 2019 Plan, the "Plans"), which reduced the per share exercise price of each Repriced Option to $4.04, representing the closing price of the Issuer's common stock on The Nasdaq Global Market on the Repricing Date (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect.

F2 · derivative.exercise_date: This stock option award was issued pursuant to the 2019 Plan and/or the 2022 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.

SEC source: 0001894562-25-000046 · wk-form4_1754440982.xml · derivative · entry 2

Foster-Cheek Kaye I · CIK 0001312622 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,510

Underlying: Common Stock · 13,510 shares

Expires 2032-01-24

F1 · kind: Effective as of August 1, 2025 (the "Repricing Date"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Stock Option and Grant Plan, as amended (the "2019 Plan") and/or the 2022 Stock Option and Incentive Plan (the "2022 Plan" and, together with the 2019 Plan, the "Plans"), which reduced the per share exercise price of each Repriced Option to $4.04, representing the closing price of the Issuer's common stock on The Nasdaq Global Market on the Repricing Date (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect.

F1 · price: Effective as of August 1, 2025 (the "Repricing Date"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Stock Option and Grant Plan, as amended (the "2019 Plan") and/or the 2022 Stock Option and Incentive Plan (the "2022 Plan" and, together with the 2019 Plan, the "Plans"), which reduced the per share exercise price of each Repriced Option to $4.04, representing the closing price of the Issuer's common stock on The Nasdaq Global Market on the Repricing Date (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect.

F2 · derivative.exercise_date: This stock option award was issued pursuant to the 2019 Plan and/or the 2022 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.

SEC source: 0001894562-25-000046 · wk-form4_1754440982.xml · derivative · entry 1

Foster-Cheek Kaye I · CIK 0001312622 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 13,510 shares

Expires 2032-01-24

F1 · kind: Effective as of August 1, 2025 (the "Repricing Date"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Stock Option and Grant Plan, as amended (the "2019 Plan") and/or the 2022 Stock Option and Incentive Plan (the "2022 Plan" and, together with the 2019 Plan, the "Plans"), which reduced the per share exercise price of each Repriced Option to $4.04, representing the closing price of the Issuer's common stock on The Nasdaq Global Market on the Repricing Date (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect.

F1 · price: Effective as of August 1, 2025 (the "Repricing Date"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Stock Option and Grant Plan, as amended (the "2019 Plan") and/or the 2022 Stock Option and Incentive Plan (the "2022 Plan" and, together with the 2019 Plan, the "Plans"), which reduced the per share exercise price of each Repriced Option to $4.04, representing the closing price of the Issuer's common stock on The Nasdaq Global Market on the Repricing Date (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect.

F2 · derivative.exercise_date: This stock option award was issued pursuant to the 2019 Plan and/or the 2022 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.

SEC source: 0001894562-25-000043 · wk-form4_1754440956.xml · derivative · entry 2

Reine Allan · CIK 0001714023 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 850,000

Underlying: Common Stock · 850,000 shares

Expires 2034-01-17

F1 · kind: Effective as of August 1, 2025 (the "Repricing Date"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Stock Option and Grant Plan, as amended (the "2019 Plan") and/or the 2022 Stock Option and Incentive Plan (the "2022 Plan" and, together with the 2019 Plan, the "Plans"), which reduced the per share exercise price of each Repriced Option to $4.04, representing the closing price of the Issuer's common stock on The Nasdaq Global Market on the Repricing Date (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect.

F1 · price: Effective as of August 1, 2025 (the "Repricing Date"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Stock Option and Grant Plan, as amended (the "2019 Plan") and/or the 2022 Stock Option and Incentive Plan (the "2022 Plan" and, together with the 2019 Plan, the "Plans"), which reduced the per share exercise price of each Repriced Option to $4.04, representing the closing price of the Issuer's common stock on The Nasdaq Global Market on the Repricing Date (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect.

F2 · derivative.exercise_date: This stock option award was issued pursuant to the 2019 Plan and/or the 2022 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.

SEC source: 0001894562-25-000043 · wk-form4_1754440956.xml · derivative · entry 1

Reine Allan · CIK 0001714023 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 850,000 shares

Expires 2034-01-17

F1 · kind: Effective as of August 1, 2025 (the "Repricing Date"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Stock Option and Grant Plan, as amended (the "2019 Plan") and/or the 2022 Stock Option and Incentive Plan (the "2022 Plan" and, together with the 2019 Plan, the "Plans"), which reduced the per share exercise price of each Repriced Option to $4.04, representing the closing price of the Issuer's common stock on The Nasdaq Global Market on the Repricing Date (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect.

F1 · price: Effective as of August 1, 2025 (the "Repricing Date"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Stock Option and Grant Plan, as amended (the "2019 Plan") and/or the 2022 Stock Option and Incentive Plan (the "2022 Plan" and, together with the 2019 Plan, the "Plans"), which reduced the per share exercise price of each Repriced Option to $4.04, representing the closing price of the Issuer's common stock on The Nasdaq Global Market on the Repricing Date (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect.

F2 · derivative.exercise_date: This stock option award was issued pursuant to the 2019 Plan and/or the 2022 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.

SEC source: 0001894562-25-000042 · wk-form4_1754440946.xml · derivative · entry 8

Alenson Carman · CIK 0001688865 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 90,498

Underlying: Common Stock · 90,498 shares

Expires 2034-02-21

F1 · kind: Effective as of August 1, 2025 (the "Repricing Date"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Stock Option and Grant Plan, as amended (the "2019 Plan") and/or the 2022 Stock Option and Incentive Plan (the "2022 Plan" and, together with the 2019 Plan, the "Plans"), which reduced the per share exercise price of each Repriced Option to $4.04, representing the closing price of the Issuer's common stock on The Nasdaq Global Market on the Repricing Date (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect.

F1 · price: Effective as of August 1, 2025 (the "Repricing Date"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Stock Option and Grant Plan, as amended (the "2019 Plan") and/or the 2022 Stock Option and Incentive Plan (the "2022 Plan" and, together with the 2019 Plan, the "Plans"), which reduced the per share exercise price of each Repriced Option to $4.04, representing the closing price of the Issuer's common stock on The Nasdaq Global Market on the Repricing Date (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect.

F2 · derivative.exercise_date: This stock option award was issued pursuant to the 2019 Plan and/or the 2022 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.

SEC source: 0001894562-25-000042 · wk-form4_1754440946.xml · derivative · entry 7

Alenson Carman · CIK 0001688865 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 90,498 shares

Expires 2034-02-21

F1 · kind: Effective as of August 1, 2025 (the "Repricing Date"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Stock Option and Grant Plan, as amended (the "2019 Plan") and/or the 2022 Stock Option and Incentive Plan (the "2022 Plan" and, together with the 2019 Plan, the "Plans"), which reduced the per share exercise price of each Repriced Option to $4.04, representing the closing price of the Issuer's common stock on The Nasdaq Global Market on the Repricing Date (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect.

F1 · price: Effective as of August 1, 2025 (the "Repricing Date"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Stock Option and Grant Plan, as amended (the "2019 Plan") and/or the 2022 Stock Option and Incentive Plan (the "2022 Plan" and, together with the 2019 Plan, the "Plans"), which reduced the per share exercise price of each Repriced Option to $4.04, representing the closing price of the Issuer's common stock on The Nasdaq Global Market on the Repricing Date (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect.

F2 · derivative.exercise_date: This stock option award was issued pursuant to the 2019 Plan and/or the 2022 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.

SEC source: 0001894562-25-000042 · wk-form4_1754440946.xml · derivative · entry 6

Alenson Carman · CIK 0001688865 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,254

Underlying: Common Stock · 6,254 shares

Expires 2033-04-18

F1 · kind: Effective as of August 1, 2025 (the "Repricing Date"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Stock Option and Grant Plan, as amended (the "2019 Plan") and/or the 2022 Stock Option and Incentive Plan (the "2022 Plan" and, together with the 2019 Plan, the "Plans"), which reduced the per share exercise price of each Repriced Option to $4.04, representing the closing price of the Issuer's common stock on The Nasdaq Global Market on the Repricing Date (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect.

F1 · price: Effective as of August 1, 2025 (the "Repricing Date"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Stock Option and Grant Plan, as amended (the "2019 Plan") and/or the 2022 Stock Option and Incentive Plan (the "2022 Plan" and, together with the 2019 Plan, the "Plans"), which reduced the per share exercise price of each Repriced Option to $4.04, representing the closing price of the Issuer's common stock on The Nasdaq Global Market on the Repricing Date (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect.

F2 · derivative.exercise_date: This stock option award was issued pursuant to the 2019 Plan and/or the 2022 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.

SEC source: 0001894562-25-000042 · wk-form4_1754440946.xml · derivative · entry 5

Alenson Carman · CIK 0001688865 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 6,254 shares

Expires 2033-04-18

F1 · kind: Effective as of August 1, 2025 (the "Repricing Date"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Stock Option and Grant Plan, as amended (the "2019 Plan") and/or the 2022 Stock Option and Incentive Plan (the "2022 Plan" and, together with the 2019 Plan, the "Plans"), which reduced the per share exercise price of each Repriced Option to $4.04, representing the closing price of the Issuer's common stock on The Nasdaq Global Market on the Repricing Date (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect.

F1 · price: Effective as of August 1, 2025 (the "Repricing Date"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Stock Option and Grant Plan, as amended (the "2019 Plan") and/or the 2022 Stock Option and Incentive Plan (the "2022 Plan" and, together with the 2019 Plan, the "Plans"), which reduced the per share exercise price of each Repriced Option to $4.04, representing the closing price of the Issuer's common stock on The Nasdaq Global Market on the Repricing Date (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect.

F2 · derivative.exercise_date: This stock option award was issued pursuant to the 2019 Plan and/or the 2022 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.

SEC source: 0001894562-25-000042 · wk-form4_1754440946.xml · derivative · entry 4

Alenson Carman · CIK 0001688865 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 90,498

Underlying: Common Stock · 90,498 shares

Expires 2033-03-31

F1 · kind: Effective as of August 1, 2025 (the "Repricing Date"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Stock Option and Grant Plan, as amended (the "2019 Plan") and/or the 2022 Stock Option and Incentive Plan (the "2022 Plan" and, together with the 2019 Plan, the "Plans"), which reduced the per share exercise price of each Repriced Option to $4.04, representing the closing price of the Issuer's common stock on The Nasdaq Global Market on the Repricing Date (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect.

F1 · price: Effective as of August 1, 2025 (the "Repricing Date"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Stock Option and Grant Plan, as amended (the "2019 Plan") and/or the 2022 Stock Option and Incentive Plan (the "2022 Plan" and, together with the 2019 Plan, the "Plans"), which reduced the per share exercise price of each Repriced Option to $4.04, representing the closing price of the Issuer's common stock on The Nasdaq Global Market on the Repricing Date (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect.

F2 · derivative.exercise_date: This stock option award was issued pursuant to the 2019 Plan and/or the 2022 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.

SEC source: 0001894562-25-000042 · wk-form4_1754440946.xml · derivative · entry 3

Alenson Carman · CIK 0001688865 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 90,498 shares

Expires 2033-03-31

F1 · kind: Effective as of August 1, 2025 (the "Repricing Date"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Stock Option and Grant Plan, as amended (the "2019 Plan") and/or the 2022 Stock Option and Incentive Plan (the "2022 Plan" and, together with the 2019 Plan, the "Plans"), which reduced the per share exercise price of each Repriced Option to $4.04, representing the closing price of the Issuer's common stock on The Nasdaq Global Market on the Repricing Date (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect.

F1 · price: Effective as of August 1, 2025 (the "Repricing Date"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Stock Option and Grant Plan, as amended (the "2019 Plan") and/or the 2022 Stock Option and Incentive Plan (the "2022 Plan" and, together with the 2019 Plan, the "Plans"), which reduced the per share exercise price of each Repriced Option to $4.04, representing the closing price of the Issuer's common stock on The Nasdaq Global Market on the Repricing Date (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect.

F2 · derivative.exercise_date: This stock option award was issued pursuant to the 2019 Plan and/or the 2022 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.

SEC source: 0001894562-25-000042 · wk-form4_1754440946.xml · derivative · entry 2

Alenson Carman · CIK 0001688865 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,083

Underlying: Common Stock · 16,083 shares

Expires 2032-01-24

F1 · kind: Effective as of August 1, 2025 (the "Repricing Date"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Stock Option and Grant Plan, as amended (the "2019 Plan") and/or the 2022 Stock Option and Incentive Plan (the "2022 Plan" and, together with the 2019 Plan, the "Plans"), which reduced the per share exercise price of each Repriced Option to $4.04, representing the closing price of the Issuer's common stock on The Nasdaq Global Market on the Repricing Date (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect.

F1 · price: Effective as of August 1, 2025 (the "Repricing Date"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Stock Option and Grant Plan, as amended (the "2019 Plan") and/or the 2022 Stock Option and Incentive Plan (the "2022 Plan" and, together with the 2019 Plan, the "Plans"), which reduced the per share exercise price of each Repriced Option to $4.04, representing the closing price of the Issuer's common stock on The Nasdaq Global Market on the Repricing Date (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect.

F2 · derivative.exercise_date: This stock option award was issued pursuant to the 2019 Plan and/or the 2022 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.

SEC source: 0001894562-25-000042 · wk-form4_1754440946.xml · derivative · entry 1

Alenson Carman · CIK 0001688865 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 16,083 shares

Expires 2032-01-24

F1 · kind: Effective as of August 1, 2025 (the "Repricing Date"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Stock Option and Grant Plan, as amended (the "2019 Plan") and/or the 2022 Stock Option and Incentive Plan (the "2022 Plan" and, together with the 2019 Plan, the "Plans"), which reduced the per share exercise price of each Repriced Option to $4.04, representing the closing price of the Issuer's common stock on The Nasdaq Global Market on the Repricing Date (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect.

F1 · price: Effective as of August 1, 2025 (the "Repricing Date"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Stock Option and Grant Plan, as amended (the "2019 Plan") and/or the 2022 Stock Option and Incentive Plan (the "2022 Plan" and, together with the 2019 Plan, the "Plans"), which reduced the per share exercise price of each Repriced Option to $4.04, representing the closing price of the Issuer's common stock on The Nasdaq Global Market on the Repricing Date (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect.

F2 · derivative.exercise_date: This stock option award was issued pursuant to the 2019 Plan and/or the 2022 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.

SEC source: 0001415889-25-021025 · form4-08052025_080848.xml · nonDerivative · entry 1

GV 2021 GP, L.L.C. · CIK 0001861206 · 10% owner

GV 2021 GP, L.P. · CIK 0001861216 · 10% owner

GV 2021, L.P. · CIK 0001861202 · 10% owner

Alphabet Inc. · CIK 0001652044 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By GV 2021, L.P.

Disclosed balance after: 3,262,440

F1 · kind: Represents shares purchased in connection with an underwritten public offering of the Issuer's Common Stock that closed on August 1, 2025.

F2 · ownership.nature: The securities reported in this row are directly beneficially owned by GV 2021, L.P. (the "2021 Partnership"). The general partner of the 2021 Partnership is GV 2021 GP, L.P. (the "2021 GP"). The general partner of the 2021 GP is GV 2021 GP, L.L.C. ("GV 2021 LLC"). The sole member of GV 2021 LLC is Alphabet Holdings LLC ("Alphabet Holdings"). The sole member of Alphabet Holdings is XXVI Holdings Inc. ("XXVI"). The controlling stockholder of XXVI is Alphabet Inc. Each of the 2021 GP, GV 2021 LLC, Alphabet Holdings, XXVI, and Alphabet Inc. may be deemed to indirectly beneficially own (as the term is defined in Rule 13d-3 of the Securities Exchange Act of 1934, as amended) the securities directly beneficially owned by the 2021 Partnership. Each of the aforementioned parties disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.

SEC source: 0001628280-25-033754 · wk-form4_1751400224.xml · nonDerivative · entry 1

Liu David R. · CIK 0001664439 · 10% owner

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 20,240,945

F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 3, 2025.

F2 · price: The price reported in column 4 is a weighted-average price. These shares were purchased in multiple transactions at prices ranging from $2.44 to $2.65, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

SEC source: 0001628280-25-032626 · wk-form4_1750710792.xml · nonDerivative · entry 1

Liu David R. · CIK 0001664439 · 10% owner

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 20,219,945

F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 3, 2025.

F2 · price: The price reported in column 4 is a weighted-average price. These shares were purchased in multiple transactions at prices ranging from $2.06 to $2.25, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

SEC source: 0001628280-25-031637 · wk-form4_1750108485.xml · nonDerivative · entry 1

Liu David R. · CIK 0001664439 · 10% owner

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 20,198,945

F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 3, 2025.

F2 · price: The price reported in column 4 is a weighted-average price. These shares were purchased in multiple transactions at prices ranging from $1.46 to $1.52, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

SEC source: 0001628280-25-031045 · wk-form4_1749761367.xml · nonDerivative · entry 1

Liu David R. · CIK 0001664439 · 10% owner

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 20,177,945

F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 3, 2025.

F2 · price: The price reported in column 4 is a weighted-average price. These shares were purchased in multiple transactions at prices ranging from $1.53 to $1.67, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

SEC source: 0001628280-25-029769 · wk-form4_1749161355.xml · derivative · entry 1

Chung Wendy · CIK 0001922605 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 55,000

Underlying: Common Stock · 55,000 shares

Expires 2035-06-04

F1 · derivative.exercise_date: The shares subject to this option shall vest in full upon the earlier of (i) June 4, 2026 or (ii) the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer through such vesting date.

SEC source: 0001628280-25-029768 · wk-form4_1749161263.xml · derivative · entry 1

Cahill Thomas · CIK 0001922939 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 55,000

Underlying: Common Stock · 55,000 shares

Expires 2035-06-04

F1 · derivative.exercise_date: The shares subject to this option shall vest in full upon the earlier of (i) June 4, 2026 or (ii) the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer through such vesting date.

SEC source: 0001628280-25-029774 · wk-form4_1749161387.xml · derivative · entry 1

Schenkein David P · CIK 0001578200 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 55,000

Underlying: Common Stock · 55,000 shares

Expires 2035-06-04

F1 · derivative.exercise_date: The shares subject to this option shall vest in full upon the earlier of (i) June 4, 2026 or (ii) the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer through such vesting date.

SEC source: 0001628280-25-029773 · wk-form4_1749161395.xml · derivative · entry 1

Marrazzo Jeffrey D · CIK 0001631262 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 55,000

Underlying: Common Stock · 55,000 shares

Expires 2035-06-04

F1 · derivative.exercise_date: The shares subject to this option shall vest in full upon the earlier of (i) June 4, 2026 or (ii) the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer through such vesting date.

SEC source: 0001628280-25-029772 · wk-form4_1749161379.xml · derivative · entry 1

NELSEN ROBERT · CIK 0001219042 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 55,000

Underlying: Common Stock · 55,000 shares

Expires 2035-06-04

F1 · derivative.exercise_date: The shares subject to this option shall vest in full upon the earlier of (i) June 4, 2026 or (ii) the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer through such vesting date.

SEC source: 0001628280-25-029771 · wk-form4_1749161372.xml · derivative · entry 1

Kelly Michael Aaron · CIK 0001769668 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 55,000

Underlying: Common Stock · 55,000 shares

Expires 2035-06-04

F1 · derivative.exercise_date: The shares subject to this option shall vest in full upon the earlier of (i) June 4, 2026 or (ii) the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer through such vesting date.

SEC source: 0001628280-25-029770 · wk-form4_1749161364.xml · derivative · entry 1

Foster-Cheek Kaye I · CIK 0001312622 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 55,000

Underlying: Common Stock · 55,000 shares

Expires 2035-06-04

F1 · derivative.exercise_date: The shares subject to this option shall vest in full upon the earlier of (i) June 4, 2026 or (ii) the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer through such vesting date.

SEC source: 0001894562-25-000028 · wk-form4_1747945273.xml · nonDerivative · entry 1

LEE ANN L. · CIK 0001723629 · Chief Technical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 100,000

SEC source: 0001894562-25-000026 · wk-form4_1747945107.xml · nonDerivative · entry 1

Reine Allan · CIK 0001714023 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 125,000

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.13 to $1.20, inclusive. The reporting person undertakes to provide to the issuer, any shareholder of the issuer or the staff of the Securities and Exchange Commission, upon request, information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

SEC source: 0001894562-25-000030 · wk-form4_1747945354.xml · nonDerivative · entry 1

Brudnick Richard · CIK 0001692359 · Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,000

SEC source: 0001894562-25-000024 · wk-form4_1747698326.xml · derivative · entry 1

Marrazzo Jeffrey D · CIK 0001631262 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 800,000

Underlying: Common Stock · 800,000 shares

Expires not disclosed

F1 · derivative.exercise_date: 500,000 of the shares underlying this option shall vest and become exercisable in twenty-four (24) equal monthly installments over a two-year period commencing from May 19, 2025; 300,000 of the shares underlying this option shall vest and become exercisable in three equal installments based on the Issuer's satisfaction of certain performance criteria tied to stock price, in each case subject to the Reporting Person's continued service on each such vesting date.

F1 · derivative.expiration_date: 500,000 of the shares underlying this option shall vest and become exercisable in twenty-four (24) equal monthly installments over a two-year period commencing from May 19, 2025; 300,000 of the shares underlying this option shall vest and become exercisable in three equal installments based on the Issuer's satisfaction of certain performance criteria tied to stock price, in each case subject to the Reporting Person's continued service on each such vesting date.

SEC source: 0001894562-25-000023 · wk-form4_1747698248.xml · derivative · entry 1

Reine Allan · CIK 0001714023 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,000,000

Underlying: Common Stock · 2,000,000 shares

Expires not disclosed

F1 · derivative.exercise_date: 25% of the shares underlying this option shall vest and become exercisable on May 19, 2026, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.

F1 · derivative.expiration_date: 25% of the shares underlying this option shall vest and become exercisable on May 19, 2026, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.

SEC source: 0001894562-25-000018 · wk-form4_1747082905.xml · derivative · entry 1

LEE ANN L. · CIK 0001723629 · Chief Technical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 241,248

Underlying: Common Stock · 80,416 shares

Expires 2031-10-27

F1 · derivative.exercise_date: Represents an option initially granted to the Reporting Person on October 27, 2021, a portion of which shares underlying this option shall vest upon the achievement of certain performance milestones. On May 8, 2025, the board of directors of the Issuer determined that one of the performance milestone conditions was achieved, resulting in the vesting of 80,416 shares.

SEC source: 0001894562-25-000019 · wk-form4_1747082995.xml · derivative · entry 1

Gottesdiener Keith Michael · CIK 0001615856 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 300,000

Underlying: Common Stock · 100,000 shares

Expires 2034-02-25

F1 · derivative.exercise_date: Represents an option initially granted to the Reporting Person on February 25, 2024, a portion of which shares underlying this option shall vest upon the achievement of certain performance milestones. On May 8, 2025, the board of directors of the Issuer determined that one of the performance milestone conditions was achieved, resulting in the vesting of 100,000 shares.

SEC source: 0001894562-25-000020 · wk-form4_1747083048.xml · derivative · entry 1

Reine Allan · CIK 0001714023 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 850,000

Underlying: Common Stock · 75,000 shares

Expires 2034-01-17

F1 · derivative.exercise_date: Represents an option initially granted to the Reporting Person on January 17, 2024, a portion of which shares underlying this option shall vest upon the achievement of certain performance milestones. On May 8, 2025, the board of directors of the Issuer determined that one of the performance milestone conditions was achieved, resulting in the vesting of 75,000 shares.

SEC source: 0001894562-25-000014 · wk-form4_1741122898.xml · derivative · entry 1

Gottesdiener Keith Michael · CIK 0001615856 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 500,000

Underlying: Common Stock · 500,000 shares

Expires 2035-02-28

F1 · derivative.exercise_date: 1/48th of the shares underlying this option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of February 28, 2025, subject to the Reporting Person's continued service on each such vesting date.

SEC source: 0001894562-25-000010 · wk-form4_1741051009.xml · derivative · entry 1

Goldwasser Meredith · CIK 0001922606 · SVP, Strategy & Corporate Ops.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 90,500

Underlying: Common Stock · 90,500 shares

Expires 2035-02-27

F1 · derivative.exercise_date: 1/48th of the shares underlying this option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of February 27, 2025, subject to the Reporting Person's continued service on each such vesting date.

SEC source: 0001894562-25-000008 · wk-form4_1741050933.xml · derivative · entry 1

Duffield Jeremy · CIK 0001922590 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 275,000

Underlying: Common Stock · 275,000 shares

Expires 2035-02-27

F1 · derivative.exercise_date: 1/48th of the shares underlying this option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of February 27, 2025, subject to the Reporting Person's continued service on each such vesting date.

SEC source: 0001894562-25-000012 · wk-form4_1741051100.xml · derivative · entry 1

Alenson Carman · CIK 0001688865 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 90,500

Underlying: Common Stock · 90,500 shares

Expires 2035-02-27

F1 · derivative.exercise_date: 1/48th of the shares underlying this option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of February 27, 2025, subject to the Reporting Person's continued service on each such vesting date.

SEC source: 0001894562-25-000006 · wk-form4_1741050835.xml · derivative · entry 1

LEE ANN L. · CIK 0001723629 · Chief Technical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 275,000

Underlying: Common Stock · 275,000 shares

Expires 2035-02-27

F1 · derivative.exercise_date: 1/48th of the shares underlying this option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of February 27, 2025, subject to the Reporting Person's continued service on each such vesting date.

SEC source: 0001894562-25-000004 · wk-form4_1741050750.xml · derivative · entry 1

Brudnick Richard · CIK 0001692359 · Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 225,000

Underlying: Common Stock · 225,000 shares

Expires 2035-02-27

F1 · derivative.exercise_date: 1/48th of the shares underlying this option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of February 27, 2025, subject to the Reporting Person's continued service on each such vesting date.

SEC source: 0001894562-25-000002 · wk-form4_1741050667.xml · derivative · entry 1

Reine Allan · CIK 0001714023 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 275,000

Underlying: Common Stock · 275,000 shares

Expires 2035-02-27

F1 · derivative.exercise_date: 1/48th of the shares underlying this option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of February 27, 2025, subject to the Reporting Person's continued service on each such vesting date.

SEC source: 0001894562-24-000049 · wk-form4_1733786581.xml · derivative · entry 1

Gottesdiener Keith Michael · CIK 0001615856 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 200,000

Underlying: Common Stock · 100,000 shares

Expires 2034-02-25

F1 · derivative.exercise_date: Represents an option initially granted to the Reporting Person on February 25, 2024, a portion of which shares underlying this option shall vest on February 25, 2025 upon the achievement of certain performance milestones. On December 5, 2024, the board of directors of the Issuer determined that one of the performance milestone conditions was achieved. As a result, the shares underlying this option shall vest on February 25, 2025, subject to the Reporting Person's continued service through such vesting date.

SEC source: 0001894562-24-000048 · wk-form4_1733786573.xml · derivative · entry 1

Brudnick Richard · CIK 0001692359 · Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 57,900

Underlying: Common Stock · 19,300 shares

Expires 2032-08-04

F1 · derivative.exercise_date: Represents an option initially granted to the Reporting Person on August 4, 2022, a portion of which shares underlying this option shall vest upon the achievement of certain performance milestones. On December 5, 2024, the board of directors of the Issuer determined that one of the performance milestone conditions was achieved, resulting in the vesting of 19,300 shares.

SEC source: 0001894562-24-000047 · wk-form4_1733786555.xml · derivative · entry 1

Reine Allan · CIK 0001714023 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 775,000

Underlying: Common Stock · 75,000 shares

Expires 2034-01-17

F1 · derivative.exercise_date: Represents an option initially granted to the Reporting Person on January 17, 2024, a portion of which shares underlying this option shall vest upon the achievement of certain performance milestones. On December 5, 2024, the board of directors of the Issuer determined that one of the performance milestone conditions was achieved, resulting in the vesting of 75,000 shares.